Outlook Therapeutics Inc Sustainability Reports
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is an ophthalmic formulation of bevacizumab designed to treat wet age-related macular degeneration and other retinal diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 5493007AWUJ6HPMCBH11
FIGI: BBG00469JRM1
3 reports from 2020 to 2024
